BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35628296)

  • 1. MicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6 × Tg Alzheimer's Disease Model Mice.
    Kang S; Kim J; Lee SY; Okamura N; Chang KA
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer's disease with PET imaging agents
    Son HJ; Jeong YJ; Yoon HJ; Lee SY; Choi GE; Park JA; Kim MH; Lee KC; Lee YJ; Kim MK; Cho K; Kang DY
    BMC Neurosci; 2018 Jul; 19(1):45. PubMed ID: 30053803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
    Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (S)-[
    Alzghool OM; Rokka J; López-Picón FR; Snellman A; Helin JS; Okamura N; Solin O; Rinne JO; Haaparanta-Solin M
    Neuropharmacology; 2021 Sep; 196():108676. PubMed ID: 34216585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
    Harada R; Okamura N; Furumoto S; Furukawa K; Ishiki A; Tomita N; Tago T; Hiraoka K; Watanuki S; Shidahara M; Miyake M; Ishikawa Y; Matsuda R; Inami A; Yoshikawa T; Funaki Y; Iwata R; Tashiro M; Yanai K; Arai H; Kudo Y
    J Nucl Med; 2016 Feb; 57(2):208-14. PubMed ID: 26541774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
    Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
    Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Sanabria Bohórquez S; Marik J; Ogasawara A; Tinianow JN; Gill HS; Barret O; Tamagnan G; Alagille D; Ayalon G; Manser P; Bengtsson T; Ward M; Williams SP; Kerchner GA; Seibyl JP; Marek K; Weimer RM
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2077-2089. PubMed ID: 31254035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.
    Imabayashi E; Tamamura N; Yamaguchi Y; Kamitaka Y; Sakata M; Ishii K
    Ann Nucl Med; 2022 Oct; 36(10):865-875. PubMed ID: 35821311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
    Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
    Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical study on [
    Xu M; Guo J; Gu J; Zhang L; Liu Z; Ding L; Fu H; Ma Y; Liang S; Wang H
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):652-663. PubMed ID: 34292345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice.
    Liu B; Le KX; Park MA; Wang S; Belanger AP; Dubey S; Frost JL; Holton P; Reiser V; Jones PA; Trigg W; Di Carli MF; Lemere CA
    J Neurosci; 2015 Nov; 35(47):15716-30. PubMed ID: 26609163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of amyloid distribution by [
    Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
    Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.